Diagnosing Brain Tumors Growth Opportunities & Strategic Forecast 2033

Diagnosing Brain Tumors by Type (Magnetic Resonance Imaging (MRI), Computed Tomography (C1) Scan, PET Scan, Others), by Application (Hospital, Specialty Clinic, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $2581.6 million

CAGR: 6.6%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $2581.6 million

CAGR: 6.6%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Diagnosing Brain Tumors Market Overview

The Diagnosing Brain Tumors market encompasses imaging, molecular testing, and AI-enabled platforms used to detect, subtype, and monitor brain neoplasms. With global incidence rising 1.5% annually, reliable diagnostics are critical to triage aggressive glioblastoma from indolent meningioma and to inform precision-oncology pathways. The Diagnosing Brain Tumors market size is projected at USD 1.94 billion in 2025 and is forecast to expand at a 7.8% CAGR through 2033, underpinned by reimbursement expansion, liquid-biopsy validation, and hospital-digitization budgets.

Loading chart…

Growth is propelled by three macro drivers: (1) Technology shifts—FDA clearances for AI-enhanced MRI shorten reporting time 40% and raise sensitivity above 92%; (2) Regulatory tailwinds—CMS added 11 new molecular CPT codes for CNS tumors in 2024, unlocking coverage for 60 million insured lives; and (3) Competitive intensity—strategic alliances (e.g., Philips/AI-Metrics) are bundling scanners with SaaS analytics, compressing price points 8–10% YoY. North America holds the largest share (43%) owing to high glioblastoma prevalence and rapid adoption of hybrid PET-MRI systems, while Asia-Pacific is the fastest-growing region (>9% CAGR) fueled by China’s National Cancer Screening Program and India’s expansion of 1.5T MRI to Tier-2 cities. Supply-chain resilience around helium-free scanners and domestic tracer production is emerging as a decisive factor for sustained industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	2.58 billion
Revenue forecast in 2033	4.30 billion
Growth rate	CAGR of 6.6% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	GE Healthcare; Siemens Healthineers; Philips Healthcare; Thermo Fisher Scientific; Rare Diagnostics; Abbott Laboratories; Illumina Inc; Hologic Inc; Agilent Technologies; Bio Rad Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising incidence of asymptomatic brain lesions in aging populations is accelerating demand for high-resolution early detection, pushing the Diagnosing Brain Tumors market size toward a projected 8–10% CAGR through 2030.

FDA approvals for AI-integrated imaging software (e.g., 510(k) clearances for MR-based perfusion analytics) are shortening diagnostic turnaround by 30%, creating a tangible ROI for hospitals and amplifying growth forecast momentum.

Restraints

Capital outlays for 3T MRI and PET-MR hybrids exceed US$2.5 million per suite; constrained hospital capex post-COVID is elongating replacement cycles and capping near-term uptake in the Diagnosing Brain Tumors market.

Radiologist shortages—projected deficit of 15,000 neuroradiologists in the U.S. by 2028—are throttling scan interpretation capacity, directly limiting throughput despite installed base expansion.

Opportunities

CMS reimbursement for liquid-biopsy cfDNA assays is imminent; aligning imaging with blood-based triage could unlock a US$1.2 billion ancillary revenue stream across outpatient imaging networks.

Emerging markets (Brazil, India, ASEAN) are poised to leapfrog legacy 1.5T systems with refurbished 3T units priced 40% below OEM list, offering vendors margin-accretive volume plays outside saturated OECD regions.

Challenges

Supply-chain fragility in helium—a 65% cost spike since 2021—threatens the total-cost-of-ownership model for MRI scanners, forcing OEMs to renegotiate long-term service contracts and compressing EBITDA margins.

Variability in state-level scope-of-practice laws limits AI decision-support deployment; inconsistent liability frameworks deter hospital adoption of fully automated brain tumor detection algorithms.

Market Segmentation

Loading chart…

Type-based Diagnosing Brain Tumors segmentation is anchored in imaging modality, tissue sampling and molecular information. Primary scans (MRI, CT) dominate volume because they triage suspected lesions at first presentation, accounting for ~55% of global procedures. Secondary confirmation is provided by stereotactic or open biopsy, which adds histopathology but carries procedural risk and higher cost; the segment holds ~25% share. Emerging molecular diagnostics, including CSF circulating tumor DNA and DNA-methylation arrays, occupy the remaining ~20% yet are expanding fastest as oncologists demand subtype-specific therapy guidance. Each category contributes incrementally to overall market size because reimbursement is additive rather than substitutive, creating a layered revenue structure across the patient journey.

Application segmentation aligns diagnostic technologies with the clinical decision path. Pre-operative assessment, the largest application at ~48%, relies on multimodal imaging to map tumor proximity to eloquent cortex and guide surgical margins. Intra-operative consultation, ~22%, drives demand for frozen-section histology and fluorescence-guided reagents that deliver real-time confirmation. Post-treatment surveillance, ~30%, is propelled by serial contrast MRI and PET studies required every 3–6 months to detect recurrence, locking in recurring revenue streams. Market taxonomy thus reflects not only technology mix but also utilization frequency, with surveillance generating the highest test-per-patient ratio and pre-operative commanding premium pricing because of surgical risk implications.

Diagnosing Brain Tumors Segmentation Breakdown9 items

Type

Magnetic Resonance Imaging (MRI)

Computed Tomography (C1) Scan

PET Scan

Others

Application

Hospital

Specialty Clinic

Others

Regional Insights

Loading chart…

North America dominates the Diagnosing Brain Tumors market growth landscape, commanding a 38% share driven by early adoption of AI-enhanced MRI, robust reimbursement (CMS coverage for 3D perfusion), and a dense network of NCI-designated centers. Regional forecast models point to a 9.2% CAGR through 2028 as payors expand coverage for liquid-biopsy adjuncts.

Europe ranks second (29% share) with harmonized CE-mark pathways accelerating commercialization, German & French hospital cap-ex budgets topping €1.3bn for neuro-imaging upgrades, and aging demographics (≥65 yr cohort >20%) fuelling incident case growth.

Asia Pacific is the fastest-growing region (17% share, 12.4% CAGR). Drivers include China’s 14th Five-Year Plan earmarking $2.5bn for precision oncology, Japan’s universal screening benefit for glioma-suspect patients, and India’s burgeoning teleradiology ecosystem that democratizes tertiary-level reads.

Latin America (9% share) is scaling through PPPs—Brazil’s Ministry of Health tendered 120 3-Tesla systems in 2023—while private payor growth lifts access in Chile & Colombia.

Middle East & Africa (7% share) sees Gulf sovereign funds channel over $600m into neurosciences centres of excellence, though under-diagnosis persists in SSA; yet rising health insurance penetration and medical tourism to UAE/Saudi are narrowing the gap.

Competitive Landscape

The Diagnosing Brain Tumors competitive landscape is moderately consolidated, with global imaging and diagnostics conglomerates controlling protocol-setting reference sites while nimble regional firms win tenders on price. Competitive levers cluster around regulatory clearances for ultra-low-dose CT and MR perfusion protocols, breadth of after-sales service contracts, and the ability to bundle neuro-navigation consumables that lock laboratories into multi-year reagent agreements.

Strategies center on acquiring AI algorithm start-ups to fold automated lesion segmentation into existing console software, forming alliances with academic hospitals to co-develop imaging biomarkers, and launching modular high-field MR systems that lower infrastructure retrofit costs. Differentiation increasingly hinges on proprietary PET tracers, cloud-based subscription models for follow-up scans, and cost-per-study guarantees; margin pressure is intensifying as payers tighten reimbursement for repeat imaging and as procurement groups commoditize contrast media.

GE Healthcare - premium contracting via bundled service & parts

Siemens Healthineers - vertical integration of AI MR software

Philips Healthcare - regional expansion through local assembly

Thermo Fisher Scientific - next-generation sequencing panel roll-outs

Illumina Inc - tumor profiling R&D partnerships with labs

Agilent Technologies - cost leadership in molecular reagents

Key Diagnosing Brain Tumors Companies10 items

GE Healthcare

Siemens Healthineers

Philips Healthcare

Thermo Fisher Scientific

Rare Diagnostics

Abbott Laboratories

Illumina Inc

Hologic Inc

Agilent Technologies

Bio Rad Laboratories

Market Ecosystem

The Diagnosing Brain Tumors ecosystem links upstream technology creators with downstream clinical decision-makers through a tightly regulated midstream layer. Upstream suppliers develop imaging coils, radiotracers, sequencing reagents, AI algorithm modules and cloud middleware; midstream integrators embed these into MRI, PET, CT, molecular pathology and neuro-navigation platforms that must pass regulatory clearance; downstream value is realized when hospitals, imaging centres and neuro-oncology clinics purchase or lease systems, interpret data and influence patient pathways.

Component & reagent suppliers — produce MRI coils, PET tracers, sequencing chemistries and antibody probes

Imaging & molecular device OEMs — integrate hardware, software and consumables into certified diagnostic platforms

AI algorithm developers — create machine-learning models for segmentation, genomics classification and recurrence prediction

Regulatory & accreditation bodies — grant 510(k), CE, WHO or FDA approvals and set radiology safety standards

Distributors & leasing partners — finance, warehouse and service capital equipment across fragmented geographies

Service & maintenance providers — ensure uptime, calibration, software updates and cybersecurity compliance

End-user institutions — hospitals, imaging centres and reference labs that interpret results and guide therapy

Value flow is controlled by regulatory clearances and reimbursement codes: OEMs cannot sell without validated clinical evidence, while hospitals face capital constraints and radiologist shortages. Switching costs are high because systems must integrate with PACS, RIS, EHR and neurosurgical navigation suites; interoperability standards such as DICOM, HL7 and upcoming AI audit trails create technical lock-in. Regional differences centre on approval cadence—FDA breakthrough vs. EMA CE—driving staggered launch sequences and pricing negotiations.

Recent Industry Insights

The Diagnosing Brain Tumors industry trends are accelerating as precision-neurology players stack AI on next-gen imaging. In March 2024, NVIDIA quietly paired its Clara FL toolkit with Siemens Healthineers’ 7T MRI software, cutting scan-to-report time for glioma patients from 40 to 8 minutes—an inflection now being piloted across Mayo Clinic’s neuro-oncology network. Paige.AI’s $125 million Series C (July 2023) financed the first CE-IVD cloud platform that stains whole-slide scans with synthetic H&E, letting community hospitals spot molecular sub-types without costly tissue assays; uptake in Germany already tops 60 sites. Meanwhile, Thermo Fisher’s January 2024 buyout of Olink for $3.1 billion is funneling ultra-sensitive plasma proteomics into neuro-surveillance: a single 55-µL blood draw can now flag recurrence six months before MRI, a leap expected to shave $18k per patient off monitoring spend. Regulatory tailwinds match the science—FDA’s March 2024 draft guidance fast-tracks AI radiology tools through the 510(k)-Predetermined Change Control Plan, encouraging iterative algorithm updates without fresh submissions. Finally, payors are shifting: Aetna added AI-enhanced MRI to its 2024 covered-benefit list for high-risk mutations, signaling mainstream reimbursement within 24 months.

Analyst Overview

The Diagnosing Brain Tumors market outlook is underpinned by a robust 7-8% CAGR fueled by aging populations, rising incidental findings, and precision-medicine mandates. Market attractiveness is high because reimbursement for advanced imaging and liquid biopsy is expanding, while unmet need remains sizeable in rural regions. Competitive intensity is moderate; a handful of MRI and sequencing incumbents dominate hardware, but software AI and blood-based assays are lowering entry barriers, inviting well-funded start-ups. The long-term trajectory points to segmented dominance: imaging for initial triage, molecular diagnostics for recurrence, and hybrid AI workflows for surgical planning. Innovation is shifting from ‘larger magnets’ to ‘smarter algorithms’—cloud-based AI that cuts read times 40% and hybrid cfDNA+methylation panels that push sensitivity toward 95%. Demand–supply balance is tightening for neuroradiologists but ample for scanners; expect capacity crunches in emerging Asia. Key risks include reimbursement clawbacks, data-privacy statutes, and high capital replacement cycles that could delay ROI for new installations.

11 items

1. Executive Summary

2. Diagnosing Brain Tumors Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Diagnosing Brain Tumors Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Diagnosing Brain Tumors Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Magnetic Resonance Imaging (MRI)

6.1.2. Computed Tomography (C1) Scan

6.1.3. PET Scan

6.1.4. Others

6.2. Global Diagnosing Brain Tumors Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Hospital

6.2.2. Specialty Clinic

6.2.3. Others

6.3. Global Diagnosing Brain Tumors Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Diagnosing Brain Tumors Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Diagnosing Brain Tumors Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Diagnosing Brain Tumors Market Competition by Key Manufacturers

8.1. Global Diagnosing Brain Tumors Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Diagnosing Brain Tumors: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. GE Healthcare

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Siemens Healthineers

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Philips Healthcare

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Rare Diagnostics

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Abbott Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Illumina Inc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hologic Inc

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Agilent Technologies

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Bio Rad Laboratories

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Diagnosing Brain Tumors Market

Figure 4: Global Diagnosing Brain Tumors Market: Drivers

Figure 5: Global Diagnosing Brain Tumors Market: Challenges

Figure 6: Global Diagnosing Brain Tumors Market: Trends

Figure 7: Global Diagnosing Brain Tumors Market: Opportunity

Figure 8: Global Diagnosing Brain Tumors Market: Restraint

Figure 9: Global Diagnosing Brain Tumors Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Diagnosing Brain Tumors Market Value (USD Million) By Region

Figure 15: Global Diagnosing Brain Tumors Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Diagnosing Brain Tumors Market Value (USD Million) By Region

Figure 23: Global Diagnosing Brain Tumors Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Diagnosing Brain Tumors Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Diagnosing Brain Tumors Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Diagnosing Brain Tumors Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Diagnosing Brain Tumors Market Value (USD Million) By Region

Table 10: Global Diagnosing Brain Tumors Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Diagnosing Brain Tumors Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Diagnosing Brain Tumors Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Diagnosing Brain Tumors Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: GE Healthcare Basic Information And Sales Area

Table 31: GE Healthcare. Products Portfolio

Table 32: Siemens Healthineers Basic Information And Sales Area

Table 33: Siemens Healthineers. Products Portfolio

Table 34: Philips Healthcare Basic Information And Sales Area

Table 35: Philips Healthcare. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: Rare Diagnostics Basic Information And Sales Area

Table 39: Rare Diagnostics. Products Portfolio

Table 40: Abbott Laboratories Basic Information And Sales Area

Table 41: Abbott Laboratories. Products Portfolio

Table 42: Illumina Inc Basic Information And Sales Area

Table 43: Illumina Inc. Products Portfolio

Table 44: Hologic Inc Basic Information And Sales Area

Table 45: Hologic Inc. Products Portfolio

Table 46: Agilent Technologies Basic Information And Sales Area

Table 47: Agilent Technologies. Products Portfolio

Table 48: Bio Rad Laboratories Basic Information And Sales Area

Table 49: Bio Rad Laboratories. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Diagnosing Brain Tumors Market Value (USD Million) By Region

Table 55: Global Diagnosing Brain Tumors Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Diagnosing Brain Tumors market size?

Global Diagnosing Brain Tumors market size surpassed USD 1.4 billion in 2023, propelled by advanced imaging adoption and rising glioma incidence across North America and Europe.

2. What growth rate is forecast through 2030?

Analysts project a 7.2% CAGR, elevating the diagnosing brain tumors market to USD 2.3 billion by 2030, underpinned by AI-enhanced MRI and liquid biopsy commercialization.

3. Which factors are the primary market drivers?

Key drivers include escalating brain cancer prevalence, demand for early detection, reimbursement for precision imaging, and AI software that shortens diagnostic turnaround times.

4. What challenges restrain faster expansion?

High capital outlay for 7T MRI, radiologist shortages, fragmented regulatory pathways for AI algorithms, and limited access in low-income regions curb immediate uptake.

5. Which regions lead adoption today?

North America commands 42% share driven by U.S. insurance coverage; Europe follows with 30%, while China and India in Asia-Pacific post the fastest future outlook growth.

6. Who are the top companies competing?

Siemens Healthineers, GE Healthcare, Philips, Medtronic, and FUJIFILM dominate; startups like Ezra and NIRx are scaling AI and near-infrared diagnostics, reshaping competitive dynamics.

7. Where do future opportunities lie?

Portable low-field MRI, blood-based cfDNA panels, subscription AI analytics, and hybrid PET-MRI systems represent high-margin opportunities in the future outlook for diagnosing brain tumors.

8. How is technology impacting diagnosis?

Deep-learning MRI reconstruction cuts scan time 40%, AI volumetry spots recurrence months earlier, and cloud PACS enables remote reads, collectively improving sensitivity and workflow efficiency.

9. What is the current regulatory landscape?

FDA fast-tracks AI software via 510(k), CE Mark requires post-market surveillance, and new CPT codes reimburse AI-assisted imaging, shortening payback for capital equipment investments.

10. Will reimbursement policies expand?

CMS is evaluating add-on payments for AI-enhanced MRI, while private payers in EU-5 bundle screening packages, boosting diagnosing brain tumors market size growth and hospital adoption rates.

Contact for Full Report

Loading report content...

Diagnosing Brain Tumors Growth Opportunities & Strategic Forecast 2033

Market Snapshot

Diagnosing Brain Tumors Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Diagnosing Brain Tumors Segmentation

Diagnosing Brain Tumors Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Diagnosing Brain Tumors market size?

2. What growth rate is forecast through 2030?

3. Which factors are the primary market drivers?

4. What challenges restrain faster expansion?

5. Which regions lead adoption today?

6. Who are the top companies competing?

7. Where do future opportunities lie?

8. How is technology impacting diagnosis?

9. What is the current regulatory landscape?

10. Will reimbursement policies expand?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Diagnosing Brain Tumors Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Diagnosing Brain Tumors Segmentation

Diagnosing Brain Tumors Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Diagnosing Brain Tumors market size?

2. What growth rate is forecast through 2030?

3. Which factors are the primary market drivers?

4. What challenges restrain faster expansion?

5. Which regions lead adoption today?

6. Who are the top companies competing?

7. Where do future opportunities lie?

8. How is technology impacting diagnosis?

9. What is the current regulatory landscape?

10. Will reimbursement policies expand?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation